{"id": "HPRD50.d0.s0_HPRD50.d0.s0.p2", "text": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "text_with_entity_marker": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and [E1]TFIIIC63[/E1]) of human [E2]TFIIIC[/E2] and their involvement in functional interactions with TFIIIB and RNA polymerase III", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIIC63", "entity_1_idx": [[85, 93]], "entity_1_idx_in_text_with_entity_marker": [89, 97], "entity_1_type": "pm0100174", "entity_1_type_id": 1, "entity_2": "TFIIIC", "entity_2_idx": [[104, 110]], "entity_2_idx_in_text_with_entity_marker": [117, 123], "entity_2_type": "pm0120026", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "HPRD50.d1.s1_HPRD50.d1.s1.p2", "text": "The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity", "text_with_entity_marker": "The receptor binding site of MCP-1 also is significantly different from the binding sites of [E1]RANTES[/E1] and [E2]IL-8[/E2], providing insight into the issue of receptor specificity", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[93, 99]], "entity_1_idx_in_text_with_entity_marker": [97, 103], "entity_1_type": "pm0105763", "entity_1_type_id": 6, "entity_2": "IL-8", "entity_2_idx": [[104, 108]], "entity_2_idx_in_text_with_entity_marker": [117, 121], "entity_2_type": "pm0121149", "entity_2_type_id": 7}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s0_HPRD50.d5.s0.p0", "text": "Cytohesin-1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with LFA-1", "text_with_entity_marker": "[E1]Cytohesin-1[/E1] regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with [E2]LFA-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cytohesin-1", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "pm0124251", "entity_1_type_id": 20, "entity_2": "LFA-1", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "pm0104657||pm0114514", "entity_2_type_id": 21}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s5_HPRD50.d5.s5.p0", "text": "Thus, cytohesin-1 is involved in the activation of LFA-1, most probably through direct interaction with the integrin, and induces cell spreading by its ARF-GEF activity", "text_with_entity_marker": "Thus, [E1]cytohesin-1[/E1] is involved in the activation of [E2]LFA-1[/E2], most probably through direct interaction with the integrin, and induces cell spreading by its ARF-GEF activity", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cytohesin-1", "entity_1_idx": [[6, 17]], "entity_1_idx_in_text_with_entity_marker": [10, 21], "entity_1_type": "pm0124251", "entity_1_type_id": 20, "entity_2": "LFA-1", "entity_2_idx": [[51, 56]], "entity_2_idx_in_text_with_entity_marker": [64, 69], "entity_2_type": "pm0104657||pm0114514", "entity_2_type_id": 21}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s4_HPRD50.d6.s4.p0", "text": "Immunoprecipitation experiments revealed a physical association of Jak2 with p125FAK via STAT3 in vivo", "text_with_entity_marker": "Immunoprecipitation experiments revealed a physical association of [E1]Jak2[/E1] with p125FAK via [E2]STAT3[/E2] in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Jak2", "entity_1_idx": [[67, 71]], "entity_1_idx_in_text_with_entity_marker": [71, 75], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "STAT3", "entity_2_idx": [[89, 94]], "entity_2_idx_in_text_with_entity_marker": [102, 107], "entity_2_type": "pm0118656", "entity_2_type_id": 25}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p3", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the NF-E2/[E1]AP-1[/E1] site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor [E2]NRF2[/E2] (NF-E2-related factor 2)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AP-1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0103880", "entity_1_type_id": 29, "entity_2": "NRF2", "entity_2_idx": [[235, 239]], "entity_2_idx_in_text_with_entity_marker": [248, 252], "entity_2_type": "pm0105918||pm0123857", "entity_2_type_id": 27}], "directed": false, "reverse": false}
{"id": "HPRD50.d9.s0_HPRD50.d9.s0.p1", "text": "Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)", "text_with_entity_marker": "Here, we cloned and characterized a mouse orthologue of human [E1]KIAA1427[/E1] protein as an atypical Syt (named [E2]Syt XIII[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KIAA1427", "entity_1_idx": [[62, 70]], "entity_1_idx_in_text_with_entity_marker": [66, 74], "entity_1_type": "pm0110335", "entity_1_type_id": 34, "entity_2": "Syt XIII", "entity_2_idx": [[105, 113]], "entity_2_idx_in_text_with_entity_marker": [118, 126], "entity_2_type": "pm0110335", "entity_2_type_id": 34}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s1_HPRD50.d10.s1.p0", "text": "The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins CD43 and P-selectin glycoprotein ligand 1 (CD162), respectively", "text_with_entity_marker": "The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins [E1]CD43[/E1] and [E2]P-selectin glycoprotein ligand 1[/E2] (CD162), respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD43", "entity_1_idx": [[91, 95]], "entity_1_idx_in_text_with_entity_marker": [95, 99], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "P-selectin glycoprotein ligand 1", "entity_2_idx": [[100, 132]], "entity_2_idx_in_text_with_entity_marker": [113, 145], "entity_2_type": "pm0119091", "entity_2_type_id": 38}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s3_HPRD50.d10.s3.p1", "text": "Finally, sialoadhesin bound different glycoforms of CD43 expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on CD43 in resting and activated T cells, respectively", "text_with_entity_marker": "Finally, [E1]sialoadhesin[/E1] bound different glycoforms of CD43 expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on [E2]CD43[/E2] in resting and activated T cells, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sialoadhesin", "entity_1_idx": [[9, 21]], "entity_1_idx_in_text_with_entity_marker": [13, 25], "entity_1_type": "pm0108007", "entity_1_type_id": 37, "entity_2": "CD43", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0122945", "entity_2_type_id": 36}], "directed": false, "reverse": false}
{"id": "HPRD50.d12.s1_HPRD50.d12.s1.p1", "text": "In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner", "text_with_entity_marker": "In this report, we demonstrate the stable association of [E1]PLCgamma1[/E1] with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of [E2]PLCgamma1[/E2], but also inhibits its enzymatic activity in a dose-dependent manner", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PLCgamma1", "entity_1_idx": [[57, 66]], "entity_1_idx_in_text_with_entity_marker": [61, 70], "entity_1_type": "pm0126499", "entity_1_type_id": 42, "entity_2": "PLCgamma1", "entity_2_idx": [[176, 185]], "entity_2_idx_in_text_with_entity_marker": [189, 198], "entity_2_type": "pm0126499", "entity_2_type_id": 42}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p3", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a [E1]phospho-LIS1[/E1] isoform and dynactin to MT bundles, raising the possibility that [E2]CLIP-170[/E2] and LIS1 regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phospho-LIS1", "entity_1_idx": [[80, 92]], "entity_1_idx_in_text_with_entity_marker": [84, 96], "entity_1_type": "phospho-pm0110467", "entity_1_type_id": 45, "entity_2": "CLIP-170", "entity_2_idx": [[158, 166]], "entity_2_idx_in_text_with_entity_marker": [171, 179], "entity_2_type": "pm0124985", "entity_2_type_id": 43}], "directed": false, "reverse": false}
{"id": "HPRD50.d14.s0_HPRD50.d14.s0.p0", "text": "Megalin and cubilin: multifunctional endocytic receptors", "text_with_entity_marker": "[E1]Megalin[/E1] and [E2]cubilin[/E2]: multifunctional endocytic receptors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Megalin", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0100604", "entity_1_type_id": 46, "entity_2": "cubilin", "entity_2_idx": [[12, 19]], "entity_2_idx_in_text_with_entity_marker": [25, 32], "entity_2_type": "pm0100963", "entity_2_type_id": 47}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p3", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "[E1]Gadd45a[/E1] (Gadd45), Gadd45b (MyD118), and [E2]Gadd45g[/E2] (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45g", "entity_2_idx": [[40, 47]], "entity_2_idx_in_text_with_entity_marker": [53, 60], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p5", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a ([E1]Gadd45[/E1]), [E2]Gadd45b[/E2] (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45b", "entity_2_idx": [[18, 25]], "entity_2_idx_in_text_with_entity_marker": [31, 38], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p14", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), Gadd45b (MyD118), and [E1]Gadd45g[/E1] ([E2]CR6[/E2]) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45g", "entity_1_idx": [[40, 47]], "entity_1_idx_in_text_with_entity_marker": [44, 51], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "CR6", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "pm0102392||pm0116690", "entity_2_type_id": 55}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s4_HPRD50.d16.s4.p2", "text": "In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo", "text_with_entity_marker": "In this work, we show that Gadd45b and [E1]Gadd45g[/E1] specifically interact with the [E2]Cdk1[/E2]/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45g", "entity_1_idx": [[39, 46]], "entity_1_idx_in_text_with_entity_marker": [43, 50], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "Cdk1", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p4", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and [E1]Gadd45g[/E1], as well as [E2]GADD45a[/E2], interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45g", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "GADD45a", "entity_2_idx": [[65, 72]], "entity_2_idx_in_text_with_entity_marker": [78, 85], "entity_2_type": "pm0112301", "entity_2_type_id": 54}], "directed": false, "reverse": false}
{"id": "HPRD50.d17.s0_HPRD50.d17.s0.p0", "text": "DGKdelta (type II isozyme) contains a pleckstrin homology domain at the N terminus and a sterile alpha motif domain at the C terminus", "text_with_entity_marker": "[E1]DGKdelta[/E1] (type II isozyme) contains a [E2]pleckstrin[/E2] homology domain at the N terminus and a sterile alpha motif domain at the C terminus", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "DGKdelta", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "pm0126604", "entity_1_type_id": 56, "entity_2": "pleckstrin", "entity_2_idx": [[38, 48]], "entity_2_idx_in_text_with_entity_marker": [51, 61], "entity_2_type": "pm0125262", "entity_2_type_id": 57}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s1_HPRD50.d18.s1.p1", "text": "The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "text_with_entity_marker": "The [E1]receptor-like protein tyrosine phosphatase[/E1] DEP1, also known as [E2]CD148[/E2], is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "receptor-like protein tyrosine phosphatase", "entity_1_idx": [[4, 46]], "entity_1_idx_in_text_with_entity_marker": [8, 50], "entity_1_type": "pm0104157", "entity_1_type_id": 58, "entity_2": "CD148", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s2_HPRD50.d18.s2.p0", "text": "DEP1 also interacted with other members of the catenin gene family including beta-catenin and gamma-catenin", "text_with_entity_marker": "[E1]DEP1[/E1] also interacted with other members of the catenin gene family including [E2]beta-catenin[/E2] and gamma-catenin", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DEP1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0115917", "entity_1_type_id": 59, "entity_2": "beta-catenin", "entity_2_idx": [[77, 89]], "entity_2_idx_in_text_with_entity_marker": [90, 102], "entity_2_type": "pm0126674", "entity_2_type_id": 61}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s4_HPRD50.d18.s4.p0", "text": "Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific", "text_with_entity_marker": "Catalytic domains of the tyrosine phosphatases [E1]PTP-PEST[/E1], [E2]CD45[/E2], and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTP-PEST", "entity_1_idx": [[47, 55]], "entity_1_idx_in_text_with_entity_marker": [51, 59], "entity_1_type": "pm0117107", "entity_1_type_id": 63, "entity_2": "CD45", "entity_2_idx": [[57, 61]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "pm0110536", "entity_2_type_id": 64}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s0_HPRD50.d19.s0.p1", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "text_with_entity_marker": "[E1]p300[/E1]/cAMP-response-element-binding-protein ('[E2]CREB[/E2]')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "CREB", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s0_HPRD50.d21.s0.p1", "text": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system", "text_with_entity_marker": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor [E1]CB1[/E1] and the orexin 1 receptor ([E2]OX1R[/E2]) using a heterologous system", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CB1", "entity_1_idx": [[90, 93]], "entity_1_idx_in_text_with_entity_marker": [94, 97], "entity_1_type": "pm0109721", "entity_1_type_id": 71, "entity_2": "OX1R", "entity_2_idx": [[121, 125]], "entity_2_idx_in_text_with_entity_marker": [134, 138], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p1", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "[E1]Gab1[/E1] and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as [E2]Grb2[/E2], Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Grb2", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "pm0105419", "entity_2_type_id": 77}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p5", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by [E1]NudC[/E1] with mutations in the [E2]Plk1[/E2] phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[217, 221]], "entity_1_idx_in_text_with_entity_marker": [221, 225], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s1_HPRD50.d26.s1.p1", "text": "We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome", "text_with_entity_marker": "We establish that [E1]pVHL[/E1] binds to Tat-binding protein-1 ([E2]TBP-1[/E2]), a component of the 19S regulatory complex of the proteasome", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "TBP-1", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p0", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "[E1]TBP-1[/E1] associates with the beta-domain of [E2]pVHL[/E2] and complexes with pVHL and Hif1 alpha in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP-1", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "pVHL", "entity_2_idx": [[41, 45]], "entity_2_idx_in_text_with_entity_marker": [54, 58], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s5_HPRD50.d26.s5.p0", "text": "Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1", "text_with_entity_marker": "Several distinct mutations in exon 2 of [E1]VHL[/E1] disrupt binding of [E2]pVHL[/E2] to TBP-1", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VHL", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "pVHL", "entity_2_idx": [[63, 67]], "entity_2_idx_in_text_with_entity_marker": [76, 80], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s5_HPRD50.d26.s5.p2", "text": "Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1", "text_with_entity_marker": "Several distinct mutations in exon 2 of VHL disrupt binding of [E1]pVHL[/E1] to [E2]TBP-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[63, 67]], "entity_1_idx_in_text_with_entity_marker": [67, 71], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "TBP-1", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p1", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A [E1]pVHL[/E1] mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not [E2]TBP-1[/E2], and does not promote degradation of Hif1 alpha", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[2, 6]], "entity_1_idx_in_text_with_entity_marker": [6, 10], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "TBP-1", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p2", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A [E1]pVHL[/E1] mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of [E2]Hif1 alpha[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[2, 6]], "entity_1_idx_in_text_with_entity_marker": [6, 10], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[135, 145]], "entity_2_idx_in_text_with_entity_marker": [148, 158], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p4", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade [E1]Hif1 alpha[/E1] depends in part on its interaction with [E2]TBP-1[/E2] and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hif1 alpha", "entity_1_idx": [[37, 47]], "entity_1_idx_in_text_with_entity_marker": [41, 51], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "TBP-1", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p5", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade [E1]Hif1 alpha[/E1] depends in part on its interaction with TBP-1 and suggests a new mechanism for [E2]Hif1 alpha[/E2] stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hif1 alpha", "entity_1_idx": [[37, 47]], "entity_1_idx_in_text_with_entity_marker": [41, 51], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "Hif1 alpha", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p4", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "Pinin/[E1]DRS[/E1]/memA interacts with SRp75, [E2]SRm300[/E2] and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DRS", "entity_1_idx": [[6, 9]], "entity_1_idx_in_text_with_entity_marker": [10, 13], "entity_1_type": "pm0118763", "entity_1_type_id": 96, "entity_2": "SRm300", "entity_2_idx": [[37, 43]], "entity_2_idx_in_text_with_entity_marker": [50, 56], "entity_2_type": "pm0117461", "entity_2_type_id": 98}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p3", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of perlecan, a specific [E1]heparan sulfate proteoglycan[/E1], to the [E2]beta-amyloid[/E2] protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "heparan sulfate proteoglycan", "entity_1_idx": [[82, 110]], "entity_1_idx_in_text_with_entity_marker": [86, 114], "entity_1_type": "pm0112250", "entity_1_type_id": 118, "entity_2": "beta-amyloid", "entity_2_idx": [[119, 131]], "entity_2_idx_in_text_with_entity_marker": [132, 144], "entity_2_type": "beta-pm0104696", "entity_2_type_id": 119}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p3", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and [E2]biglycan[/E2], two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "biglycan", "entity_2_idx": [[123, 131]], "entity_2_idx_in_text_with_entity_marker": [136, 144], "entity_2_type": "pm0124379", "entity_2_type_id": 115}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p10", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC [E1]PGs[/E1] bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p13", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by [E1]perlecan[/E1], weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by [E2]versican[/E2]/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[85, 93]], "entity_1_idx_in_text_with_entity_marker": [89, 97], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "versican", "entity_2_idx": [[192, 200]], "entity_2_idx_in_text_with_entity_marker": [205, 213], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d34.s1_HPRD50.d34.s1.p2", "text": "The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans", "text_with_entity_marker": "The fact that the apoB mRNA editing protein also exists as a [E1]homodimer[/E1] has important implications for the mechanism of [E2]apoB[/E2] mRNA editing in humans", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "homodimer", "entity_1_idx": [[61, 70]], "entity_1_idx_in_text_with_entity_marker": [65, 74], "entity_1_type": "pm0125626", "entity_1_type_id": 132, "entity_2": "apoB", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "pm0126272", "entity_2_type_id": 130}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s2_HPRD50.d36.s2.p0", "text": "The association of PTP-1C with CD22 was mediated by the NH2-terminal Src homology 2 (SH2) domain of PTP-1C", "text_with_entity_marker": "The association of [E1]PTP-1C[/E1] with [E2]CD22[/E2] was mediated by the NH2-terminal Src homology 2 (SH2) domain of PTP-1C", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PTP-1C", "entity_1_idx": [[19, 25]], "entity_1_idx_in_text_with_entity_marker": [23, 29], "entity_1_type": "pm0105676", "entity_1_type_id": 136, "entity_2": "CD22", "entity_2_idx": [[31, 35]], "entity_2_idx_in_text_with_entity_marker": [44, 48], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d37.s0_HPRD50.d37.s0.p5", "text": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "text_with_entity_marker": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to [E1]TAF(II)250[/E1], the core subunit of [E2]TFIID[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAF(II)250", "entity_1_idx": [[142, 152]], "entity_1_idx_in_text_with_entity_marker": [146, 156], "entity_1_type": "pm0108292", "entity_1_type_id": 138, "entity_2": "TFIID", "entity_2_idx": [[174, 179]], "entity_2_idx_in_text_with_entity_marker": [187, 192], "entity_2_type": "pm0109127", "entity_2_type_id": 137}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p3", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, [E2]loricrin[/E2], and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "loricrin", "entity_2_idx": [[265, 273]], "entity_2_idx_in_text_with_entity_marker": [278, 286], "entity_2_type": "pm0103809", "entity_2_type_id": 143}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p2", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "[E1]Bcl3[/E1] specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the [E2]GST[/E2] pull-down assays", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl3", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "GST", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
